Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

4.310
+0.0100.23%
Volume:3.70M
Turnover:15.71M
Market Cap:2.68B
PE:27.05
High:4.365
Open:4.300
Low:4.175
Close:4.300
52wk High:16.520
52wk Low:4.110
Shares:622.00M
HK Float Shares:622.33M
Volume Ratio:0.80
T/O Rate:0.59%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.159
ROE:0.33%
ROA:0.59%
PB:0.84
PE(LYR):27.05
PS:2.93

Loading ...

Bioan Biotech's BA1302 (CD228 ADC) Completes China Phase Ia Clinical Study

Stock News
·
Aug 14

BOAN Biotech Schedules 27 Aug 2026 Board Meeting to Approve 1H26 Results and Assess Interim Dividend

Bulletin Express
·
Aug 14

BOAN BIOTECH (06955) Warns of Loss, Expects Net Loss Attributable to Shareholders of Approximately RMB 79 Million to RMB 89 Million for the First Half of the Year, a Swing from Profit to Loss

Stock News
·
Aug 14

Shandong Boan Biotechnology Expects Net Loss Attributable of RMB79 Million-RMB89 Million

Reuters
·
Aug 14

Shandong Boan Biotech Completes China Phase Ia Trial of Ba1302 CD228-Targeted ADC

Reuters
·
Aug 14

Shandong Boan Biotechnology Co - Expected Turnaround to Loss Mainly Due to Increased R&D Expenditure in Hy

THOMSON REUTERS
·
Aug 14

Shandong Boan Biotech Schedules Board Meeting on Interim Results, Dividend Review

Reuters
·
Aug 14

Hong Kong Stock Movers: BOAN BIOTECH Surges Over 3% Before Noon as Aflibercept Injection Seeks Brazilian Approval

Stock News
·
Aug 11

BOAN BIOTECH Affirms Stable 622.33 Million Share Base and Meets Public-Float Waiver in July 2026 Return

Bulletin Express
·
Aug 06

Shandong Boan Biotechnology Submits BLA for Ba9101 to Anvisa in Brazil

Reuters
·
Aug 05

Shandong Boan Files Brazil Marketing Application for Ba9101 Aflibercept Biosimilar with Anvisa

Reuters
·
Aug 05

Shandong Boan Biotechnology Co - Submits Bla for Ba9101 to Anvisa in Brazil

THOMSON REUTERS
·
Aug 05

Shandong Boan Biotechnology's Cancer Drug Candidate Gets IND Acceptance; Shares Down 5%

MT Newswires Live
·
Jul 08

BOAN BIOTECH’s BA1203 IND Accepted by CDE, Marking China’s First Masked PD-1/IL-2 Fusion Protein to Enter Clinical Trials

Bulletin Express
·
Jul 08

Shandong Boan Says China CDE Accepts IND Filing for Ba1203 Masked Anti-pd-1/il-2 Fusion Protein

Reuters
·
Jul 08

Shandong Boan Biotechnology Co - Cde Accepts Ind Application for Ba1203 Targeting Pd-1 and Il-2

THOMSON REUTERS
·
Jul 08

Shandong Boan Biotechnology - Acceptance from China's Cde of Nmpa

THOMSON REUTERS
·
Jul 08

Shandong Boan Biotechnology Gets Trial Nod for Lung Cancer Drug in China

MT Newswires Live
·
Jul 02

Boan Biotech Secures CDE Approval to Advance BA1106 + BA1104 Combo into Phase II Trial for Driver-Gene-Negative NSCLC

Bulletin Express
·
Jul 02

Shandong Boan Biotechnology Co - Cde Approves Phase Ii Trial of Anti-cd25 Antibody with Pd-1 Inhibitor for Nsclc

THOMSON REUTERS
·
Jul 02